Trends in clinical profile and medical treatments of atrial fibrillation patients over the last 10 years

Revista Portuguesa de Cardiologia

Volumn 32, Issue 2, 2013, Pages 103-109

  Rodríguez Mañero, Moisés ^a   Bertomeu González, Vicente ^b   Cordero, Alberto ^b   Moreno Arribas, José ^b   Mazón, Pilar ^c   Fácila, Lorenzo ^d   Cosín, Juan ^e   Galve, Enrique ^f   Lekuona, Iñaki ^g   González Juanatey, José R ^c   Bertomeu Martínez, Vicente ^b  

^a UNIVERSITY HOSPITAL BRUSSELS   (Belgium)

^b HOSPITAL UNIVERSITARIO DE SAN JUAN   (Spain)

^c HOSPITAL CLÍNICO UNIVERSITARIO   (Spain)

^d Hospital Provincial de Castellon   (Spain)

^e HOSPITAL ARNAU DE VILANOVA   (Spain)

^f HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^g HOSPITAL DE GALDAKAO   (Spain)

Author keywords

Atrial fibrillation; Oral anticoagulation; Risk factors; Upstream therapies

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; INSULIN; NITRATE; ORAL ANTIDIABETIC AGENT;

AGE DISTRIBUTION; AGED; ANTICOAGULANT THERAPY; ARTICLE; CARDIOLOGIST; CEREBROVASCULAR ACCIDENT; CORONARY ARTERY DISEASE; DIABETES MELLITUS; FEMALE; GENERAL PRACTITIONER; HEART ATRIUM FIBRILLATION; HEART FAILURE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTPATIENT CARE; PRESCRIPTION; PREVALENCE;

EID: 84876044253     PISSN: 08702551     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.repc.2012.06.011     Document Type: Article

References (27)

1. Feinberg WM, Blackshear JL, Laupacis A, et al. Prevalence, age distribution and gender of patients with atrial fibrillation: analysis and implications. Arch Intern Med. 1995;155:469-73.
2. Braunwald E. Shattuck Lecture-Cardiovascular medicine at the turn of the millennium: triumphs, concerns and opportunities. N Engl J Med. 1997;337:1360-9. (Pubitemid 27467771)
3. Stefansdottir H, Aspelund T, Gudnason V, et al. Trends in the incidence and prevalence of atrial fibrillation in Iceland and future projections. Europace. 2011;13:1110-7.
4. Wolf PA, Benjamin EJ, Belanger AJ, et al. Secular trends in the prevalence of atrial fibrillation: the Framingham Study. Am Heart J. 1996;131:790-5. (Pubitemid 26116354)
5. Friberg J, Scharling H, Gadsböll N, et al. Sex-specific increase in the prevalence of atrial fibrillation (The Copenhagen City Heart Study). Am J Cardiol. 2003;92:1419-23. (Pubitemid 37532563)
6. García-Acuña JM, González-Juanatey JR, Alegría E, et al. La fibrilación auricular permanente en las enfermedades cardiovasculares en España. Estudio CARDIOTENS 1999. Rev Esp Cardiol. 2002;55:943-52. (Pubitemid 35175170)
7. Cordero A, Bertomeu-Martínez V, Mazón P, et al. Factors associated with uncontrolled hypertension in patients with and without cardiovascular disease. Rev Esp Cardiol. 2011;64:587-93.
8. Chalmers J, MacMahon S, Mancia G, et al. World Health Organization-International Society of Hypertension Guidelines for the management of hypertension. Guidelines sub-committee of the World Health Organization. Clin Exp Hypertens. 1999;21:1009-60. (Pubitemid 29325497)
9. Mancia G, De Backer G, Dominiczak A, et al. Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J. 2007;28:1462-536.
10. Levey AS, Coresh J, Greene T, et al., Chronic Kidney Disease Epidemiology Collaboration. Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate. Ann Intern Med. 2006;145:247-54. (Pubitemid 46768608)
11. Gersh BJ, Tsang TS, Seward JB. The changing epidemiology and natural history of nonvalvular atrial fibrillation: clinical implications. Trans Am Clin Climatol Assoc. 2004;115:149-59.
12. Kannel WB, Abbott RD, Savage DD, et al. Epidemiologic features of chronic atrial fibrillation: the Framingham study. N Engl J Med. 1982;306:1018-22. (Pubitemid 12155370)
13. McGovern PG, Jacobs Jr DR, Shahar E, et al. Trends in acute coronary heart disease mortality, morbidity, and medical care from 1985 through 1997: the Minnesota Heart Survey. Circulation. 2001;104:19-24. (Pubitemid 32623284)
14. Benjamin EJ, Levy D, Vaziri SM, et al. Independent risk factors for atrial fibrillation in a population-based cohort: the Framingham Heart Study. J Am Med Assoc. 1994;271:840-4.
15. Camm AJ, Kirchhof P, Lip GY, et al. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of the European Society of Cardiology (ESC). Eur Heart J. 2010;19:2369-429.
16. Rodríguez-Mañero M, Cordero A, Bertomeu-González V, et al. Impact of new criteria for anticoagulant treatment in atrial fibrillation. Rev Esp Cardiol. 2011;64:649-53.
17. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med. 2007;146:857-67. (Pubitemid 351650486)
18. Connolly S, Pogue J, Hart R, et al. Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial. Lancet. 2006;367:1903-12.
19. Peterson GM, Boom K, Jackson SL, et al. Doctors' beliefs on the use of antithrombotic therapy in atrial fibrillation: identifying barriers to stroke prevention. Intern Med J. 2002;32:15-23. (Pubitemid 36124632)
20. Dinh T, Nieuwlaat R, Tieleman RG, et al. Antithrombotic drug prescription in atrial fibrillation and its rationale among general practitioners, internists and cardiologists in The Netherlands - The EXAMINE-AF study. A questionnaire survey. Int J Clin Pract. 2007;61:24-31.
21. Segal JB, McNamara RL, Miller MR, et al. The evidence regarding the drugs used for ventricular rate control. J Fam Pract. 2000;49:47-59. (Pubitemid 30489236)
22. Yan AT, Yan RT, Liu PP. Narrative review: pharmacotherapy for chronic heart failure: evidence from recent clinical trials. Ann Intern Med. 2005;142:132-45.
23. Cordero A, Bertomeu-Martínez V, Mazón P, et al. Differences in medical treatment of chronic coronary heart disease patients according to medical specialities. Cardiovasc Ther. 2009;27:173-80.
24. Kotseva K, Wood D, De BG, et al. Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet. 2009;373:929-40.
25. Bhatt DL, Eagle KA, Ohman EM, et al., REACH Registry Investigators. Comparative determinants of 4-year cardiovascular event rates in stable outpatients at risk of or with atherothrombosis. J Am Med Assoc. 2010;304:1350-7.
26. Falaschetti E, Chaudhury M, Mindell J, et al. Continued improvement in hypertension management in England: results from the Health Survey for England 2006. Hypertension. 2009;53:480-6.
27. Dewilde S, Carey IM, Richards N, et al. Trends in secondary prevention of ischaemic heart disease in the UK 1994-2005: use of individual and combination treatment. Heart. 2008;94:83-8.